BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Amphora Discovery Corporation To Present Posters On Promising Results From AKT And Target Tyrosine Kinase (TTK) Programs At AACR-NCI-EORTC International Conference


11/8/2005 11:29:05 AM

RESEARCH TRIANGLE PARK, N.C., Nov. 8 /PRNewswire/ -- Amphora Discovery Corporation today announced that abstracts containing promising data from Amphora's preclinical AKT and Targeted Tyrosine Kinase (TTK) programs have been accepted for poster presentation at the AACR-NCI-EORTC International Conference in Philadelphia, Pennsylvania November 14 -18, 2005.

Details are as follows: - Presentation Time: November 15th 12.30 - 2.30 pm.; 5.30 - 7.30 pm Poster Session A Title: Multi-Targeted Tyrosine Kinase Inhibitors of FLT3 + cKIT + PDGFR for the Treatment of Hematological Malignancies and Solid Tumors. Poster A264 - Amphora will present data on several proprietary series of inhibitors that are highly selective for the combination of FLT3 + cKIT + PDGFR over a broad panel of 96 enzymes. These inhibitors have been rapidly optimized and demonstrate low nanomolar potency in blocking proliferation in a leukemia cell line. - Presentation Time: November 17th 12.30 - 2.30 pm.; 5.30 - 7.30 pm Session C Title: Is One Enough? - Development of Highly Selective AKT1 Inhibitors as a Targeted Therapy for Cancer. Poster C147 - Amphora will present the latest data on potent compounds that are highly selective for the AKT1 isoform. These compounds display nanomolar inhibitory activity and are >100-fold selective over AKT2, AKT3, and 96 other enzyme targets. Cellular assays addressing apoptosis, proliferation, and phosphorylation of downstream substrates with the AKT1 selective inhibitors will be shown. About Amphora

Amphora is a biopharmaceutical company with a pipeline of internally discovered product candidates that address oncology and inflammation indications. The company is engaged in the discovery and development of superior, highly-selective, small molecule medicines for both large and small markets. By leveraging its robust and proprietary chemical-biological database, Amphora is pursuing a next generation drug discovery strategy. Amphora's preclinical programs include AKT1, p38, and TRPV1 as well as partnered programs. For more information, please visit the company's web site at www.amphoracorp.com.

Amphora Discovery Corporation

CONTACT: Tracy Thompson, Corporate Communications of Amphora,+1-919-287-6177, or Tracy.Thompson@amphoracorp.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES